Evidence map›Paper›PMID 31718011›Full record

ArticleInternational journal of molecular sciences2019

Anti-Inflammatory and Anti-Hyperuricemic Functions of Two Synthetic Hybrid Drugs with Dual Biological Active Sites.

Rafa S Almeer, Sherif F Hammad, Ola F Leheta, Ahmed E Abdel Moneim, Hatem K Amin

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. GreenJournal of diabetes research · 2020
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Rafa S AlmeerDepartment of Zoology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-1624-3109
Sherif F HammadDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Cairo 11795, Egypt.ORCID 0000-0001-8869-5967
Ola F LehetaClinical Pathology Department, Faculty of Medicine, Suez Canal University, Ismalia 41522, Egypt.
Ahmed E Abdel MoneimDepartment of Zoology and Entomology, Faculty of Science, Helwan University, Cairo 11795, Egypt.ORCID 0000-0002-2654-2591
Hatem K AminDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University, Cairo 11795, Egypt.
Helwan University · EGKing Saud University · SASuez Canal University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to test the anti-inflammatory and xanthine oxidase inhibitory activities of two synthesized molecules and compare them to routinely prescribed nonsteroidal anti-inflammatory drugs (NSAIDs), such as diclofenac and the serum urate-lowering drug, allopurinol. The anti-inflammatory effects of the designed compounds (A and B) were evaluated in carrageenan (CAR)-induced paw edema in mice. The levels of nitric oxide and myeloperoxidase activity were measured in paw skin using biochemical methods. Additionally, prostaglandin E2 (PGE2), C-reactive protein (CRP), cyclooxygenase-2 (Cox-2), tumor necrosis factor-α (TNFα), interleukin (IL)-1β, IL-2 and IL-10, and monocyte chemoattractant protein-1 (MCP1) were assessed by enzyme-linked immunosorbent assay (ELISA). The expression of inflammation-related genes was confirmed by real-time qPCR. The expression of inducible nitric oxide synthase (iNOS) and nuclear factor-kappa B (NF-κB) were estimated using immunohistochemistry, and xanthine oxidase inhibitory activity was evaluated using an in vitro assay. The results revealed that compounds A and B decreased inflammation, as was observed by a reduction in the elevation of all the tested markers. In addition, the tested compounds markedly decreased paw swelling, mobilization of inflammatory cells, iNOS-, and NF-κB-immunoreactive cells in a mouse model of paw edema. Interestingly, both compounds were potent xanthine oxidase inhibitors as well as Cox inhibitors with higher activity in favor of compound B providing potential dual acting series of anti-hyperuricemic and anti-inflammatory therapeutic agents.

Indexed as

AnimalsAnti-Inflammatory AgentsCells, CulturedChemokine CCL2C-Reactive ProteinCyclooxygenase 2DinoprostoneEdemaGout SuppressantsInterleukinsMaleMiceNF-kappa BNitric OxideNitric Oxide Synthase Type IIPeroxidaseAnti-Inflammatory AgentsChemokine CCL2C-Reactive ProteinCyclooxygenase 2DinoprostoneGout SuppressantsInterleukinsNF-kappa BNitric OxideNitric Oxide Synthase Type IIPeroxidaseTumor Necrosis Factor-alphaXanthine Oxidaseallopurinolarthritisdiclofenacfebuxostatinflammationpaw edemaxanthine oxidase

Identifiers

PMID31718011
PMCPMC6888696
OpenAlexW2985850138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.